Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

Nature medicine·2026

Same author

Selpercatinib in Early-Stage <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer.

The New England journal of medicine·2026

Same author

SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

Nature medicine·2026

Same author

Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumors.

Frontiers in oncology·2026

Same author

Brief report: Artificial intelligence meets small cell lung cancer-integrating clinicopathological and wholeslide image data for prognostic prediction in SCLC.

Frontiers in artificial intelligence·2026

Same author

Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors.

Investigational new drugs·2026

Search research articles

Related Experiment Video

Updated: Apr 12, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Immunologic checkpoint blockade in lung cancer.

Martin Reck¹, Luis Paz-Ares²

¹Department of Thoracic Oncology, LungenClinic Grosshansdorf, Airway Research Center North (ARCN), Grosshansdorf, Germany.

Seminars in Oncology

|May 13, 2015

Summary

Novel immuno-oncology therapies targeting immune checkpoints show promise for improving outcomes in non-small cell lung cancer (NSCLC) patients ineligible for surgery. Research is ongoing to optimize these treatments.

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

Related Experiment Videos

Last Updated: Apr 12, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

Area of Science:

Oncology
Immunology

Background:

Lung cancer patients ineligible for surgery have limited treatment options.
Immuno-oncology, particularly targeting immune checkpoints, is a promising research area.
General immunostimulatory agents have shown early promise.

Purpose of the Study:

To examine the rationale for targeting immune checkpoints in lung cancer.
To review clinical data for immune checkpoint inhibitors in development.
To discuss challenges in optimizing these treatments for lung cancer.

Main Methods:

Review of clinical trial data for immune checkpoint inhibitors.
Examination of the scientific rationale for targeting CTLA-4 and PD-1 receptors.
Discussion of treatment optimization strategies.

Main Results:

Immune checkpoint inhibitors targeting CTLA-4 and PD-1 show potential in early clinical trials for NSCLC.
These agents may improve tumor response and survival rates.
Further research is needed to overcome treatment challenges.

Conclusions:

Targeting immune checkpoints represents a significant advancement in lung cancer therapy.
Immune checkpoint inhibitors offer new hope for patients with non-small cell lung cancer.
Optimizing the use of these novel agents is crucial for maximizing patient benefit.